Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)

被引：0

作者：

Venkatesh, Pradeep ^{[1
]}

机构：

[1] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dis Retina Vitreous & Uvea, New Delhi, India

来源：

OPHTHALMOLOGY | 2017年 / 124卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

引用

页码：E37 / E38

页数：3

共 27 条

[21] Re: Heier et al.: Intravitreal combined aflibercept plus antieplatelet-derived growth factor receptor β for neovascular age-related macular degeneration: results of the phase 2 CAPELLA trial (Ophthalmology. 2020;127:211-220) REPLY
Brown, David M.
OPHTHALMOLOGY, 2021, 128 (10) : E70 - E70
[22] Re: Heier et al.: Intravitreal combined aflibercept plus anti-platelet-derived growth factor receptor β for neovascular age-related macular degeneration: results of the phase 2 CAPELLA trial (Ophthalmology. 2020;127:211-220)
Nelson, Mark
OPHTHALMOLOGY, 2021, 128 (10) : E69 - E70
[23] Re: Samuelson et al.: Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results (Ophthalmology. 2019;126:811-821)
Melo Araujo, Karina Carvalho
Velanes Neto, Elson Cabral
Bassoli Scoralick, Ana Luiza
Kanadani, Fabio Nishimura
Prata, Tiago Santos
OPHTHALMOLOGY, 2020, 127 (02) : E14 - E15
[24] Re: Samuelson et al.: Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results (Ophthalmology. 2019;126:811-821) REPLY
Samuelson, Thomas W.
OPHTHALMOLOGY, 2020, 127 (02) : E15 - E16
[25] Re: Zucherman JF, Hsu KY, Hartjen CA, et al. A multicenter, prospective, randomized trial evaluating the X STOP interspinous process decompression system for the treatment of neurogenic intermittent claudication: Two-year follow-up results. Spine 2005; 30: 1351-8.
Weiner, BK
SPINE, 2005, 30 (24) : 2846 - 2847
[26] Re: Clinical outcomes with selectively constrained SECURE-C cervical disc arthroplasty: two year results from a prospective, randomized, controlled, multicenter investigational device exemption study. Vaccaro A, Beutler W, Peppelman W, et al. Re: Very late complications of cervical arthroplasty: results of 2 controlled randomized prospective studies from a single investigator site. Hacker F, Babcock R, Hacker R. Spine 2013; 38: 2223-39
Germon, Tim
SPINE, 2014, 39 (07) : 630 - 630
[27] Re: Clinical outcomes with selectively constrained SECURE-C cervical disc arthroplasty: two year results from a prospective, randomized, controlled, multicenter investigational device exemption study. Vaccaro A, Beutler W, Peppelman W, et al. Re: Very late complications of cervical arthroplasty: results of 2 controlled randomized prospective studies from a single investigator site. Hacker F, Babcock R, Hacker R. Spine 2013; 38: 2223-39 Response
Vaccaro, Alexander R.
Koerner, John D.
Beutler, William
Peppelman, Walter
Marzluff, Joseph M.
Highsmith, Jason
SPINE, 2014, 39 (07) : 631 - 631

← 1 2 3 →